27 JANUARY 2025 * COPENHAGEN

AI & EMERGING TECH IN LIFE SCIENCE

- UNLOCKING THE POTENTIAL

BY relevent*



LAWYERS' MANDATORY CONTINUING EDUCATION

The conference meets the requirements for lawyers' mandatory continuing education and provides 7 lessons.

IN CO-OPERATION WITH

Gorrissen Federspiel MEDWATCH ITWATCH

PARTNERS

Danish Life Science Cluster DANSK ERHVERV

SPONSOR

DIGITAL REALTY

IN CO-OPERATION WITH

MEDWATCH

MedWatch reports on the pharmaceutical and medtech industry in Denmark, which are important areas beyond the domestic commercial sector and play a vital role for public health and society in general. MedWatch delivers independent, critical and fair journalism and focuses on core substance.

ITWATCH

ITWatch closely follows Danish IT and telecommunication players, focusing on the businesses behind the products. We cover strategy, management, results, competition, policy, orders, acquisitions, innovation, careers, job moves and much more. ITWatch delivers independent, critical and fair journalism about the large, leading firms – but also the subcanopy of small and medium-sized businesses that form the

Gorrissen Federspiel

Gorrissen Federspiel is a premier law firm in Denmark, established in 1869, with robust international connections. We provide counsel across all areas of Danish and EU commercial law and maintain offices in Copenhagen and Aarhus.

CONFERENCE PARTNERS

DANSK ERHVERV

Danish Life Science Cluster

SPONSOR

DIGITAL REALTY

BY relevent*

SPEAKERS

Moderator:

Partner
Martin Dræbye Gantzhorn
Gorrissen Federspiel

Speakers:

Senior Vice President, Professor
Lene Oddershede
Novo Nordisk Foundation

Senior Advisor
Rolf Oberlin Hansen
The Danish Medicines Agency

Partner
David Telyas
Gorrissen Federspiel

Partner
Tue Goldschmieding
Gorrissen Federspiel

Quantum Engagement Specialist
Ulrich Busk Hoff
Kvantify

Chief AI Officer (CAIO)
Erik David Johnson
Delegate

CEO
Nadia Carlsten
Danish Centre for AI Innovation (DCAI)

Professor in Chemistry
Gemma C. Solomon
Novo Nordisk Foundation Quantum Computing Programme, Niels Bohr Instituttet

Senior Vice President Data Science
Thomas Senderovitz
Novo Nordisk

CEO & Partner
Ulrik Juul Rokkedal Therkildsen
Human Bytes

Department Manager of AI Technology
Casper Salinas
Gubra

Principal Data Scientist
Theodoulos Rodosthenous
Novartis

Senior Account Manager
Jesper Holdt
Digital Realty

Head of AI & Cloud Data Services
Alex Schuleit
Leo Pharma

Head of Bioinformatics
Morana Vitezic
Lundbeck

08.30-09.00 - REGISTRATION

Morning coffee

09.00-09.10 - INTRODUCTION

Moderator:
Partner **Martin Dræbye Gantzhorn,**
Gorrissen Federspiel

09.10-09.40 - QUANTUM TECHNOLOGY IN LIFE SCIENCES: TRANSFORMATIVE POTENTIAL AND FUTURE HORIZONS

In this presentation, Lene Oddershede will delve into the transformative potential of quantum technology in the life sciences sector.
As quantum computing and quantum mechanics unlock new possibilities in molecular modeling, drug discovery, and data processing, these technologies promise to redefine approaches to some of the most challenging problems in medicine and biology. Join Lene as she explores how quantum advancements are shaping the future of life sciences, the current innovations funded by the Novo Nordisk Foundation, and the upcoming challenges and ethical considerations that lie ahead.

Senior Vice President, Professor
Lene Oddershede, Novo Nordisk Foundation

09.40-10.10 - THE AI ACT – IMPLEMENTATION, INTENTIONS AND GOVERNANCE

With the final agreement on new regulation for AI in the EU, the DKMA are now closely collaborating with national, European and international colleagues to ensure legal clarity in the intersection between medical devices and AI. Hear about the regulators intentions, developments and outlook on national governance when implementing the AI Act in the Medical Device sector.

Senior Advisor **Rolf Oberlin Hansen**, The Danish Medicines Agency

10.10-10.20 - BREAK

10.20-10.50 - AI ACT: ADDRESSING FLAWS AND GAPS IN AI REGULATION

In this session, Tue and David from Gorrissen Federspiel will examine the AI Act and its implications for the life sciences sector. They will explore potential flaws and gaps in the current regulation, analyzing how these may affect AI adoption, innovation, and compliance in highly regulated industries. Their presentation will address both the legal and practical challenges posed by the AI Act, providing guidance on how companies can navigate these complexities while highlighting areas where further refinement in legislation may be needed.

Partner **David Telyas,** Gorrissen Federspiel

Partner **Tue Goldschmieding**,
Gorrissen Federspiel

10.50-11.20 - NOVEL QUANTUM AND CLASSICAL COMPUTATIONAL TOOLS FOR LIFE SCIENCES

Computational tools are indispensable for life sciences, and particularly for accelerating development in biotechnology and drug discovery by shifting early-stage work from the lab to in silico. Quantum computers are poised to impact the field profoundly once at scale, enabling novel computational chemistry and optimization solutions, but in the meantime a lot of progress can still be made on the classical side. I will exemplify this by Kvantify's new physics-based simulation tools for early-stage drug discovery. Finally, I will show how present quantum computers can already be exploited for hybrid quantum-classical simulations of enzymatic processes.

Quantum Engagement Specialist **Ulrich Busk Hoff**, Kvantify

11.20-11.35 - NETWORKING BREAK

11.35-12.10 - GENERATIVE AI AND LARGE LANGUAGE MODELS: TRANSFORMING LIFE SCIENCES WITH INNOVATION AND PRECISION

Discover how Generative AI and big language models can transform the life science sector with their ability to handle not only language, but also sound, images and complex datasets.
Chief AI Officer, Ai MVP, researcher, practitioner and expert in artificial intelligence with a focus on language technology Erik David Johnson will share insights on how this technology is changing the game in research, diagnostics and precision medicine.

This session is a must for those who want both practical examples and strategic perspectives on how Generative AI can boost innovation, reduce development time and improve treatment outcomes. With in-depth insights, you'll gain knowledge and concrete tools to take your organisation to the next level.

Chief AI Officer (CAIO) **Erik David Johnson**
Delegate

12.10-12.25 - GEFION – PIONEERING THE FUTURE OF AI ACCELERATED RESEARCH

CEO **Nadia Carlsten**,
Danish Centre for AI Innovation

12.25-12.50 - (HOW) CAN WE USE QUANTUM COMPUTING TO SOLVE SIGNIFICANT PROBLEMS IN CHEMISTRY, MATERIALS SCIENCE AND LIFE SCIENCES?

Professor in Chemistry **Gemma C. Solomon**,
Novo Nordisk Foundation Quantum Computing Programme, Niels Bohr Instituttet

12.50-13.45 - LUNCH

13.45-14.15 - AI AND QUANTUM TECHNOLOGY AT NOVO NORDISK

Thomas will share insights from Novo Nordisk and discuss the company's cross-functional work with AI and quantum technology and the potential pitfalls and applications.

Senior Vice President Data Science
Thomas Senderovitz, Novo Nordisk

14.15-14.40 - APPLIED AI FOR HEALTHCARE - REAL WORLD EXPERIENCES

Human Bytes has delivered numerous AI implementations across the Nordic countries and specialties such as radiology, radiotherapy, pathology, ophthalmology, and patient monitoring.

They will share best practices for applied AI and demonstrate how the immense potential of AI can improve workloads and patient pathways. The presentation will explore how top healthcare professionals navigate barriers, including legal, IT, and clinical concerns. Additionally, they will highlight a Nordic hospital aiming to become a global leader in applied AI, set to take ambitious and groundbreaking steps to realize the value of artificial intelligence in early 2025.

CEO & Partner **Ulrik Juul Rokkedal Therkildsen**,
Human Bytes

14.40-14.50 - BREAK

14.50-15.10 - FROM POC TO PRODUCTION: IMAGE ANALYSIS AT SCALE

Department Manager of AI Technology Casper Salinas will share insights into developing methods for efficient image analysis in drug discovery and bringing them to life through MLOps and software development. Gain a deep understanding of how technology and strategy work hand in hand in this exciting process.

Department Manager of AI Technology
Casper Salines, Gubra

15.10-15.30 - FROM DATA TO DECISIONS: MULTIMODAL AI IN CLINICAL DEVELOPMENT

A presentation of how Novartis integrates and works with AI.

Principal Data Scientist **Theodoulos Rodosthenous**, Novartis

15.30-15.40 - EMPOWER YOUR INNOVATION: SEAMLESS CONNECTIVITY AND ROBUST COMPLIANCE IN ADVANCED DATA CENTERS

Discover how Digital Realty's advanced data center infrastructure can accelerate your research, enhance product development, and drive innovation while ensuring compliance, data sovereignty, and seamless connectivity through private AI networks and dedicated connections, both locally and internationally.

Senior Account Manager **Jesper Holdt**, Digital Realty - *Sponsor Presentation*

15.40-15.45 - SHORT BREAK

15.45-16.10 - FROM TOYS TO TOOLS – ON HOW TO DRIVE TANGIBLE BUSINESS VALUE WITH AI

The presentation will present LEO Pharma's journey with AI, highlighting where they are today, their future direction and real-world cases that show the impact of AI in their organisation.

Head of AI & Cloud Data Services **Alex Schuleit**, Leo Pharma

16.10-16.35 - ACCELERATING TARGET QUALIFICATION WITH KNOWLEDGE GRAPHS

AI is undoubtedly transforming the way things are done in the drug discovery world. To ensure these tools enhance processes, organizations must adapt to new ways of working. At Lundbeck, this is achieved through a centralized R&D digital strategy that focuses on creating alignment and synergies to make the organization AI-ready. In this presentation, Morana Vitezic will share practical insights, including an example of how a specific technology was adapted to strengthen the early drug discovery toolbox, laying the groundwork for broader application across the organization and drug development processes.

Head of Bioinformatics **Morana Vitezic**, Lundbeck

16.35-16.40 - CLOSING REMARKS

Moderator:
Partner **Martin Dræbye Gantzhorn**, Gorrissen Federspiel

PRICES & PRACTICAL INFORMATION

PRICES

	EARLY BIRD BY 20 DECEMBER 2024	REGULAR FEE AFTER 20 DECEMBER 2024
FEE	DKK 5.995,- (+ VAT)	DKK 6.495,- (+ VAT)

* Registration fee includes conference delegate material, refreshments and lunch.
Accommodation is NOT included.

3-at-2 discount - 3 delegates from the same company, that register at the same time, pay the price of 2.

Members of ***The Danish Chamber of Commerce*** *and* ***Danish Life Science Cluster*** get a member discount – please inform us about your membership when registering.

DISCOUNTS CAN NOT BE COMBINED.

WHERE

Charlottehaven
Hjørringgade 12C
2100 Copenhagen Ø
Phone +45 3527 1500

WHEN

Monday 27 January 2025

REGISTRATION

Registration at https://relevent.dk/life-science-ai-quantum/
Please contact info@relevent.dk or +45 28305445 with any questions.

Cancellations must be given in writing to info@relevent.dk and will be subject to a fee.
Cancellation fee for up to 14 dayes before - 10% of registration fee.
Cancellation fee for less then 14 days before - 50% of registration fee.
Cancellation fee for later then 2 working days before - no refund, thus 100% of registration fee.

To avoid cancellation fees – you may transfer your registration to a colleague.
Please inform Relevent prior to the conference in writing to info@relevent.dk

BY relevent*